NCT05643742 - A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

January 31, 2030

Study Completion Date

February 28, 2030

Conditions

B-cell LymphomaNon-Hodgkin LymphomaB-cell MalignancyChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Follicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaLarge B-cell Lymphoma

Interventions

BIOLOGICAL

CTX112

CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)

Trial Locations (6)

2050

RECRUITING

Research Site, Camperdown

3004

RECRUITING

Research Site, Melbourne

6009

RECRUITING

Research Site, Nedlands

63110

RECRUITING

Research Site, St Louis

66205

RECRUITING

Research Site, Westwood

78229

RECRUITING

Research Site, San Antonio